Company:  KUBOTA PHARMACEUTICAL HOL ...
Form Type:  4
Filing Date:  3/20/2017 
CIK:  0001400482 
Address:  4-20-3, EBISU, SHIBUYA-KU 
City, State, Zip:  TOKYO,  150-0013 
Telephone:  813-5789-5872 
Fiscal Year:  12/31 
Description of Business
We are a clinical stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases affecting millions of people worldwide. We focus on developing oral products based on our proprietary visual cycle modulation, or ("VCM"), compounds to address a variety of retinal diseases, primarily age-related macular degeneration, or ("AMD"), diabetic retinopathy, Stargardt's disease and potentially diabetic macular edema. Our product candidates are designed to address the root cause of these diseases by reducing toxic by-products and oxidative damage as well as protecting the retina from light damage. The visual cycle is the biological conversion of a photon into an electrical signal in the retina. Our approach to treating and slowing the progression of ophthalmic diseases utilizes proprietary compounds that are intended to reduce the speed of, or modulate, the visual cycle.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES